ArticlePathology oncology research : POR2022

Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment.

Aoyun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.